Appaloosa Statement on Allergan Shareholder Vote

Approximately 40% of Shareholders Want Immediate Split of Chairman and CEO Roles

NEW YORK--(BUSINESS WIRE)-- Appaloosa LP today issued a statement following Allergan plc’s (NYSE: AGN) (“Allergan”) Annual General Meeting of Shareholders on May 1, 2019 regarding Allergan shareholder’s vote on Appaloosa’s proposal to separate the Chairman and CEO roles.

“Allergan shareholders are clearly dissatisfied with management’s performance, business strategy and board oversight, as nearly 40% of voting shareholders want more pressing change than what the Board is offering. It is incumbent on Allergan’s Board to address these shareholder concerns with concrete actions. Appaloosa continues to believe that separating the roles of Chairman and CEO is a necessary initial step toward arresting the steady decline of what was once a great company. We look forward to Allergan detailing the tangible steps the Board intends to take in order to begin the process of restoring credibility and value for its shareholders.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005721/en/

Media:
Jonathan Gasthalter/Nathaniel Garnick
Gasthalter & Co.
(212) 257-4170

Source: Appaloosa LP

You May Also Be Interested In

• Sopra Steria appoints Laura Chaubard to lead its Defence, Security and Space vertical
• ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
• Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026